Smoking Prevalence, Mortality Ranges Widely From State to State

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 4
Volume 10
Issue 4

WASHINGTON-Smoking prevalence varies considerably from state to state among both adults and students, according to new data from the Centers for Disease Control and Prevention (CDC). In 1999, adult prevalence ranged from 13.9% in

WASHINGTON—Smoking prevalence varies considerably from state to state among both adults and students, according to new data from the Centers for Disease Control and Prevention (CDC). In 1999, adult prevalence ranged from 13.9% in Utah to 31.5% in Nevada. For students (grades 9-12), the rate varied between a low of 11.9% in Utah to a high of 43.6% in South Dakota. Smoking-related deaths ranged from 188 per 100,000 population in Utah to 469 per 100,000 in Nevada. Kentucky had the highest lung cancer mortality rate in 1997, 53.2 per 100,000, and Utah had the lowest, 14.2 per 100,000.

Articles in this issue
IOM Urges Action to Fix ‘Broken’ US Health Care System
Thompson Pledges Fundamental HCFA Reform
NCCN Updates Its Practice Guideline for Breast Cancer
Smoking Prevalence, Mortality Ranges Widely From State to State
NCI Debuts New Program for Cancer Advocates
Fiberoptic Ductoscopy for Nipple Discharge DisWomen With Nipple Discharge
Augmerosen, Antisense Drug, in Phase III Testing in Melanoma
Automated System Improves Accuracy of HER-2 Scoring
Small Advantage for Adjuvant Paclitaxel in Early Breast Cancer
New HIV Guidelines Lower the Count for Starting Therapy Antiretroviral Therapy
Prostate Cancer Research at UCSF Focuses on Dendritic Cells
Pretransplant Mylotarg Boosts Survival in Relapsed AML
Thalidomide Demonstrates Multiple Roles in Myeloma
DepoCyt, Liposomal Cytarabine, Reintroduced Into US Market
Film Mammography Still the Gold Standard: IOM Report
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Related Content
Treatment with IGV-001 demonstrated a 45% increase in overall survival compared with standard of care in patients with newly diagnosed glioblastoma.

Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM

Tim Cortese
December 3rd 2025
Article

Treatment with IGV-001 demonstrated a 45% increase in overall survival compared with standard of care in patients with newly diagnosed glioblastoma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL

Ariana Pelosci
December 3rd 2025
Article

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

FDA Selects Detalimogene for Manufacturing Pilot Program in NMIBC

Roman Fabbricatore
December 3rd 2025
Article

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.